Last reviewed · How we verify
ARV-806
ARV-806 is a PROTAC (proteolysis targeting chimera) designed to degrade the androgen receptor (AR) in prostate cancer cells.
ARV-806 is a PROTAC (proteolysis targeting chimera) designed to degrade the androgen receptor (AR) in prostate cancer cells. Used for Metastatic castration-resistant prostate cancer.
At a glance
| Generic name | ARV-806 |
|---|---|
| Sponsor | Arvinas Inc. |
| Drug class | PROTAC |
| Target | Androgen Receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ARV-806 binds to the androgen receptor, leading to its ubiquitination and subsequent degradation by the proteasome, thereby reducing the levels of functional AR and inhibiting the growth of prostate cancer cells.
Approved indications
- Metastatic castration-resistant prostate cancer
Common side effects
- Fatigue
- Nausea
Key clinical trials
- A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARV-806 CI brief — competitive landscape report
- ARV-806 updates RSS · CI watch RSS
- Arvinas Inc. portfolio CI